Bayer HealthCare to set BAY86-6150 rFVIIa End I clinical figures at XXIX WFH Intercontinental Congress
Time I clinical matter due to the fact that BAY86-6150, a blockbuster recombinant element VIIa protein (rFVIIa) being developed particularly Bayer HealthCare, last wishes as be presented at the XXIX Supranational Congress of the Give birth to Society of Hemophilia (WFH) to be held in Buenos Aires, Argentina from Saturday, July 10-Wednesday, July 14.
Facts to be presented are from a facet I, randomized, double-blind, placebo-controlled, single-dose escalation survey of the rFVIIa distinct (BAY 86-6150) in hemophilia A or B with or without inhibitors Abridge #07P14). This mull over sought to gauge the safeness, tolerability, pharmacodynamic and pharmacokinetic profiles and immunogenicity of BAY 86-6150 in non-bleeding subjects with hemophilia A or hemophilia B.
Bayer is committed to expanding thorough and clinical intelligence that improves persistent take care of. At the Congress, Bayer leave be presenting evidence from other globally sponsored studies and country-sponsored programs as doubtlessly as hosting two aide symposia.
DOCUMENTATION Bayer HealthCare
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
